A clinical pharmacologist outlines the scientific, financial, and regulatory architecture that determines which compounds reach patients, comparing the scale of a single drug program to construction of the world's tallest building. The discussion clarifies why development timelines stretch across a decade and why most candidates fail before approval. For longevity medicine, these constraints shape which interventions are ever formally tested in humans.
Key Points
- Single drug programs rival megaprojects in cost, duration, and personnel
- Regulatory endpoints determine which mechanisms advance to human trials
- Most candidate compounds fail before reaching patient populations
Longevity Analysis
Therapeutic options available to any patient are filtered upstream by economics and regulatory design long before a prescription is written, which explains the scarcity of approved agents targeting aging processes directly. Understanding how endpoints are defined, how trials are financed, and where candidates fail allows clinicians to interpret the evidence behind a molecule rather than the marketing around it. That interpretive skill matters more as repurposed drugs and unapproved compounds circulate through longevity practice with widely varying support.
Original published by Peter Attia MD, by Peter Attia.